ProMIS Neurosciences (PMN) Other financing activities (2024)
ProMIS Neurosciences' (PMN) quarterly Other financing activities came in at -$1.0 in Q4 2024.
ProMIS Neurosciences (PMN) Other financing activities (2024) Analysis & Trends
ProMIS Neurosciences (PMN) has 1 years of Other financing activities data on file, last reported at -$1.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.80 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.53 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.33 Bn | 60.14 Bn | 1.37 Bn |
| 4 | Moderna | 59.76 Bn | 54.62 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.84 Bn | 28.53 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.23 Bn | 9.84 Bn | 668.28 Mn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.46 Bn | - |
| 10 | ProMIS Neurosciences | 135.44 Mn | 81.98 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -1.00 |
| Dec 31, 2024 | -1.00 |